JP2016522188A5 - - Google Patents

Download PDF

Info

Publication number
JP2016522188A5
JP2016522188A5 JP2016512076A JP2016512076A JP2016522188A5 JP 2016522188 A5 JP2016522188 A5 JP 2016522188A5 JP 2016512076 A JP2016512076 A JP 2016512076A JP 2016512076 A JP2016512076 A JP 2016512076A JP 2016522188 A5 JP2016522188 A5 JP 2016522188A5
Authority
JP
Japan
Prior art keywords
entinostat
administration
administered
conditions
combination according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016512076A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016522188A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/036651 external-priority patent/WO2014179738A1/en
Publication of JP2016522188A publication Critical patent/JP2016522188A/ja
Publication of JP2016522188A5 publication Critical patent/JP2016522188A5/ja
Pending legal-status Critical Current

Links

JP2016512076A 2013-05-03 2014-05-02 癌の処置方法 Pending JP2016522188A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361819505P 2013-05-03 2013-05-03
US61/819,505 2013-05-03
PCT/US2014/036651 WO2014179738A1 (en) 2013-05-03 2014-05-02 Methods for the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019026073A Division JP6860949B2 (ja) 2013-05-03 2019-02-15 癌の処置方法

Publications (2)

Publication Number Publication Date
JP2016522188A JP2016522188A (ja) 2016-07-28
JP2016522188A5 true JP2016522188A5 (https=) 2017-06-15

Family

ID=51843995

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016512076A Pending JP2016522188A (ja) 2013-05-03 2014-05-02 癌の処置方法
JP2019026073A Active JP6860949B2 (ja) 2013-05-03 2019-02-15 癌の処置方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019026073A Active JP6860949B2 (ja) 2013-05-03 2019-02-15 癌の処置方法

Country Status (6)

Country Link
EP (1) EP2991650A4 (https=)
JP (2) JP2016522188A (https=)
KR (1) KR102337598B1 (https=)
CN (1) CN105492007A (https=)
HK (1) HK1223547A1 (https=)
WO (1) WO2014179738A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2990687A1 (en) * 2015-06-29 2017-01-05 Syndax Pharmaceuticals, Inc. Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of cancer
JP2019524748A (ja) * 2016-07-20 2019-09-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 がんの治療におけるエリブリン及びヒストンデアセチラーゼ阻害剤の使用
CN111278459A (zh) * 2017-05-19 2020-06-12 赛达克斯制药股份有限公司 组合疗法
CA3102136A1 (en) 2018-06-06 2019-12-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
RU2680603C1 (ru) * 2018-11-08 2019-02-25 Ильясов Шамиль Сионович Применение 3-о-сульфамата-16,16-диметил-d-гомоэквиленина для лечения онкологических заболеваний

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080003334A (ko) * 2005-03-11 2008-01-07 더 리젠트스 오브 더 유니버시티 오브 콜로라도 암 세포를 표피 성장 인자 억제제에 대해 감작화시키는히스톤 데아세틸라제 억제제
US20080095843A1 (en) * 2006-07-11 2008-04-24 Nutalapati Siva R K Controlled-release formulations
WO2009067500A1 (en) * 2007-11-19 2009-05-28 Syndax Pharmaceuticals, Inc. Administration of an inhibitor of hdac
WO2009109844A1 (en) * 2008-03-07 2009-09-11 Pfizer Inc. Methods, dosage forms, and kits for administering ziprasidone without food
CA2725390C (en) * 2008-04-08 2014-09-23 Syndax Pharmaceuticals, Inc. Use of a hdac inhibitor and a her-2 inhibitor in the treatment of breast cancer
MX358254B (es) * 2011-09-02 2018-08-10 Syndax Pharmaceuticals Inc Métodos para el tratamiento de cáncer de mama.

Similar Documents

Publication Publication Date Title
NZ750754A (en) Methods of treating eosinophilic esophagitis
JP2019112416A5 (https=)
WO2017042607A3 (en) Compositions comprising meloxicam-cyclodextrin inclusion complexes and methods of treating acute pain
JP2012193216A5 (https=)
JP2016522188A5 (https=)
ZA202301198B (en) Method of treating diseases
RU2017134443A (ru) Способ лечения с применением традипитанта
JP2016520089A5 (https=)
JP2016510326A5 (https=)
EP4696301A3 (en) A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
AR091351A1 (es) Formulaciones de bromocriptina, metodo para mejorar el control glucemico y metodo para la fabricacion
JP2016512817A5 (https=)
JP2015532293A5 (ja) 糖尿病患者における心不全の治療用組成物
RU2019110980A (ru) Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением
RU2018146504A (ru) Лечение внутрипеченочных холестатических заболеваний
WO2015061790A3 (en) Genetically-associated chronic obstructive pulmonary disease treatment
JP2017514858A5 (https=)
JP2016501234A5 (https=)
JP2019528267A5 (https=)
JP2017061488A5 (https=)
WO2016122289A3 (ko) 베르베논 유도체를 포함하는 재관류 시술의 부작용을 감소 또는 예방하기 위한 조성물
JP2015535256A5 (https=)
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms
JP2019513151A5 (https=)
TW201613600A (en) Piperazinyl derivative reduces HFD-induced accumulation of fat in the liver, therapeutically